Farxiga

AstraZeneca gets US FDA nod for FARXIGA to treat chronic kidney disease

Read more

T2D market will grow from a total of $48.1bn sales in 2019 to $91.9 bn in 2029

Read more

US FDA approves AstraZeneca’s diabetes drug for treating heart failure risk

Read more

FDA gives fast track status to AstraZeneca’s diabetes drug Farxiga

Read more

AstraZeneca’s Farxiga meets main goal of heart failure study

Read more